Japan Ventures Progress Cell And Gene Candidates For ALS, Severe Conditions

BioJapan Showcases Recent Progress

Multiple Japanese ventures presented updates on their novel pipeline assets and modalities at BioJapan, including cell and gene therapies and combination treatments, despite lingering financing challenges.

BioJapan 2024 was joined by numerous ventures with novel modalities in the country (Lisa Takagi)

This year’s BioJapan meeting in Yokohama saw more than 18,000 attendees as the major annual conference and exhibition continued to regain momentum following the pandemic.

A Japan Healthcare Venture Summit program and dedicated exhibition area at the meeting, held over 8-10 October, showcased more than 100 Japanese ventures, including dozens of

More from Scrip

More from Focus On Asia